DKK 366.55
Key Takeaways
Risk factor
Low default risk
Profitability factor
Very strong margins and returns
About
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV
Target Price
The average target price of NOVO-B.CO is 472 and suggests 29% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in
